Sight Sciences insider transfer: 37,492 shares moved to irrevocable trust

Rhea-AI Filing Summary

Catherine Mazzacco, a director of Sight Sciences, Inc. (SGHT), reported on Form 4 that on 09/11/2025 she transferred 37,492 shares of the company's common stock to the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023 for no consideration. The filing shows the Reporting Person remains a beneficiary of that Trust. After the reported disposition, the Form 4 lists 41,015 shares as beneficially owned following the transaction. The Form 4 was signed by an attorney-in-fact on 09/15/2025.

Insights

Securities Analyst

TL;DR: Director transferred a material block of shares into an irrevocable trust but remains a beneficiary; transaction appears administrative.

The Form 4 documents a direct disposition of 37,492 common shares on 09/11/2025 into an irrevocable trust for no consideration, with the reporting person retaining beneficiary status. This is a Section 16 disclosure of an insider transfer rather than an open-market sale or purchase. The post-transaction beneficial ownership is reported as 41,015 shares. From a reporting perspective, the disclosure satisfies statutory requirements and provides transparency about insider holdings.

Corporate Governance Expert

TL;DR: Transfer to a personal irrevocable trust is a common governance/estate-planning action and not a change in board role.

The filing identifies Catherine Mazzacco as a director and shows the transfer to the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023 for no consideration. The form notes the reporting person is a beneficiary of the trust. There is no indication of resignation, change in board status, or sale to third parties in the filing. The signature was provided by an attorney-in-fact on 09/15/2025, indicating the filing was executed through a designated representative.

Insider Trade Summary

37,492 shares gifted

Mixed 1 txn

Insider Mazzacco Catherine

Role Director

Type	Security	Shares	Price	Value
Gift	Common Stock	37,492	$0.00	--

Holdings After Transaction: Common Stock — 41,015 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Mazzacco Catherine

(Last) (First) (Middle)

C/O SIGHT SCIENCES, INC.

4040 CAMPBELL AVE., SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		G		37,492(1)	D	$0.00	41,015	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 11, 2025, the Reporting Person transferred the shares to the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023 (the "Trust"), of which the Reporting Person is a beneficiary, for no consideration.

	/s/ Jeremy Hayden, Attorney-in-Fact for Catherine Mazzacco	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Catherine Mazzacco report on Form 4 for SGHT?

The Form 4 reports a transfer of 37,492 shares of Sight Sciences common stock on 09/11/2025 to an irrevocable trust.

How many shares does the Form 4 show Catherine Mazzacco beneficially owned after the transaction?

The filing shows 41,015 shares as beneficially owned following the reported transaction.

What is the name of the trust that received the shares?

The shares were transferred to the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023.

Did Catherine Mazzacco receive payment for the transferred shares?

No. The Form 4 states the shares were transferred to the trust for no consideration.

What is Catherine Mazzacco's relationship to Sight Sciences in this filing?

The Form 4 marks the reporting person as a Director of Sight Sciences, Inc.

When was the Form 4 signed and by whom?

The Form 4 was signed by Jeremy Hayden, Attorney-in-Fact for Catherine Mazzacco on 09/15/2025.